Description: ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease; and Clotinab, an abciximab that is used as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications. It is also developing ISU104, a human antibody for the treatment of refractory cancer; ISU304, a modified recombinant factor IX protein for the treatment of Hemophilia B patients; and ISU305, an antibody biosimilar for paroxysmal nocturnal hemoglobinuria therapy. ISU Abxis Co., Ltd. is headquartered in Seongnam, South Korea.
Home Page: www.abxis.com
Global R&D Center Building C
Seongnam-si,
13488
South Korea
Phone:
82 3 1696 4700
Officers
| Name | Title |
|---|---|
| Sang-Ho Park Ph.D. | Chief Exec. Officer |
| Chang-Hoon Choi | Exec. |
| Mr. Heung-Rok Park | Exec. |
| Joon-Young Park | Exec. |
| Mr. Seungho Kim | Exec. |
| Young-Soo Sohn | Exec. |
| Mr. Sung-Ho Choi | Exec. |
| Jin-Chul Shin | Exec. |
| Hyun-Il Kim | Exec. |
| Jae-Heung Lee | Exec. |
Exchange: KQ
Country: KR : Korea (Republic of)
Currency: Korean Won (₩)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 5.2516 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |